

Registration

Register by visiting the Center for Continuing Education in Health Sciences website at:

<https://ccehs.upmc.com/home.jsf>

Select “Upcoming Events”. Click on the appropriate event to begin registration.

All cancellations must be in writing and sent to us via U.S. mail, email or fax (see contact information below). Tuition for cancellations postmarked or date stamped before 10-13-2015 will be refunded in full. No refunds will be made after 10-13-2015.

Please send cancellations to:

Email: eganmk@upmc.edu

Fax: 412-623-3650

Mail: UPMC Cancer Pavilion, POB 2
3rd Floor, Room 354, Suite 3B
5150 Center Ave
Pittsburgh, PA 15232

Registration deadline: Friday, October 9, 2015

There is no fee for this educational activity. Registration is REQUIRED for all attendees.

Questions? Please call 412-623-3651

UNIVERSITY OF PITTSBURGH CANCER INSTITUTE

*In Celebration of 30 Years of
Cancer Research and Innovation*

PRESENTS

30th Anniversary Symposium “Cancer Drug Development”

WEDNESDAY, OCTOBER 14, 2015

8:00 AM—1:30 PM

HERBERMAN CONFERENCE CENTER

PITTSBURGH, PA



Sponsored by the University of Pittsburgh Cancer Institute, UPMC CancerCenter, and the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences.

COURSE DIRECTORS

EDWARD CHU, MD
NANCY E. DAVIDSON, MD

TARGET AUDIENCE

UPCI AND UNIVERSITY OF PITTSBURGH FACULTY MEMBERS AND FELLOWS, AS WELL AS CANCER INVESTIGATORS FROM NEARBY ACADEMIC INSTITUTIONS IN OHIO, NEW YORK, AND PENNSYLVANIA

PROGRAM OVERVIEW

THIS PROGRAM WILL PROVIDE A COMPREHENSIVE OVERVIEW OF THE CANCER DRUG DEVELOPMENT PROCESS, THE ROLE OF CANCER GENOMICS AND PHARMACOGENOMICS, AND THE ROLE OF THERAPEUTIC DRUG MONITORING IN CLINICAL ONCOLOGY PRACTICE

LEARNING OBJECTIVES

AT THE COMPLETION OF THIS ACTIVITY, PARTICIPANTS WILL BE ABLE TO:

- UNDERSTAND THE COMPLEXITY OF THE CANCER DRUG DEVELOPMENT PROCESS
- UNDERSTAND THE ROLE OF PHARMACOGENOMICS AND CANCER GENOMICS IN PERSONALIZING NOVEL AGENTS AND COMBINATION REGIMENS
- UNDERSTAND THE ROLE OF THERAPEUTIC DRUG MONITORING IN DELIVERING PERSONALIZED MEDICINE

CME ACCREDITATION

THE UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE IS ACCREDITED BY THE ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION TO PROVIDE CONTINUING MEDICAL EDUCATION FOR PHYSICIANS.

THE UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE DESIGNATES THIS LIVE ACTIVITY FOR A MAXIMUM OF 5.0 *AMA PRA CATEGORY 1 CREDIT(S)*[™]. PHYSICIANS SHOULD CLAIM ONLY THE CREDIT COMMENSURATE WITH THE EXTENT OF THEIR PARTICIPATION IN THE ACTIVITY.

OTHER HEALTH CARE PROFESSIONALS ARE AWARDED 0.5 CONTINUING EDUCATION UNITS (CEU'S) WHICH ARE EQUAL TO 5.0 CONTACT HOURS.

THE AMERICAN WITH DISABILITIES ACT

PARTICIPATION BY ALL INDIVIDUALS IS ENCOURAGED. ADVANCE NOTIFICATION OF ANY SPECIAL NEEDS WILL HELP US PROVIDE BETTER SERVICE. PLEASE NOTIFY US OF YOUR NEEDS AT LEAST TWO WEEKS IN ADVANCE OF THE PROGRAM BY CALLING MARY KATE EGAN AT 412-623-3651.

FACULTY DISCLOSURE

ALL INDIVIDUALS IN A POSITION TO CONTROL THE CONTENT OF THIS EDUCATION ACTIVITY ARE REQUIRED TO DISCLOSE ALL RELEVANT FINANCIAL RELATIONSHIPS WITH ANY PROPRIETARY ENTITY PRODUCING, MARKETING, RE-SELLING, OR DISTRIBUTING HEALTH CARE GOODS OR SERVICES, USED ON, OR CONSUMED BY, PATIENTS.

Speakers

Patricia LoRusso, DO

Professor of Medicine, Yale University School of Medicine
Associate Director, Innovative Medicine, Yale Cancer Center
New Haven, CT

Mark J. Ratain, MD

Leon O. Jacobson Professor of Medicine
Director, Center for Personalized Therapeutics
Associate Director for Clinical Sciences, Comprehensive Cancer Center
The University of Chicago
Chicago, IL

Mario Sznol, MD

Professor of Medicine (Medical Oncology)
Clinical Research Program Leader, Melanoma Program, Yale Cancer Center
Co-Director, Yale SPORE in Skin Cancer
Fitkin Memorial Pavilion
New Haven, CT

Chris H. Takimoto, MD, PhD

Vice President, Translational Medicine & Early Development
Oncology Therapeutic Area
Janssen Research & Development, LLC.
Janssen Pharmaceutical Companies of Johnson & Johnson
Spring House, PA

Anthony W. Tolcher, MD

Director of Clinical Research
START
San Antonio, TX

The University of Pittsburgh is an affirmative action, equal opportunity institution.

Speakers

Edward Chu, MD

Professor of Medicine and Pharmacology & Chemical Biology
University of Pittsburgh School of Medicine
Chief, Division of Hematology-Oncology
Deputy Director, University of Pittsburgh Cancer Institute
Pittsburgh, PA

Nancy E. Davidson, MD

Hillman Professor of Oncology & Distinguished Professor of Medicine
University of Pittsburgh School of Medicine
Director, University of Pittsburgh Cancer Institute and
UPMC CancerCenter
Associate Vice Chancellor for Cancer Research, UPCI
Pittsburgh, PA

Bruce A. Chabner, MD

Professor of Medicine, Harvard Medical School
Director of Clinical Research, MGH Cancer Center, Massachusetts
General Hospital
Boston, MA

Jerry M. Collins, PhD

Associate Director for Developmental Therapeutics
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Rockville, MD

Martha Donoghue, MD

Pediatric Solid Tumors Scientific Liaison
Clinical Reviewer for Pediatric Oncology, Neuro-Oncology, and
Rare Tumors
Office of Hematology and Oncology Products
US Food and Drug Administration
Silver Spring, MD

Agenda

7:30am	Registration & Breakfast	
8:00am	Welcome & Introduction	Nancy E. Davidson, MD
8:10am	Connecting Preclinical and Clinical Pharmacology	Jerry M. Collins, PhD
8:45am	The Role of Pharmacogenomics in Cancer Drug Development	Mark J. Ratain, MD
9:20am	The Evolution of Industry- Sponsored Early Stage Oncology Clinical Trials: The Perils of Living Large!	Chris H. Takimoto, MD, PhD
9:55am	The Role of the FDA in Cancer Drug Development: Achievements, Opportunities, and Challenges	Martha Donoghue, MD
10:30am	Break & Refreshments	
10:55am	Challenges in Immunotherapy Drug Development	Mario Sznol, MD
11:30am	Disruption in Phase I Clinical Trials	Anthony W. Tolcher, MD
12:05pm	Perspective on Targeted Drug Development for Cancer: Dealing with Drug Resistance	Bruce A. Chabner, MD
12:40pm	A Personalized Medicine Approach to Early Clinical Therapeutics	Patricia LoRusso, DO
1:15pm	Closing Remarks	Edward Chu, MD
1:25pm	Evaluations	
1:30pm	Adjournment & Lunch	